These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38240051)

  • 1. Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.
    Wei XC; Guo YY; Zhang Y; Bu YS; Zhang FY
    J Chemother; 2024 Jan; ():1-8. PubMed ID: 38240051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 3. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
    Yoon JH; Hong AR; Kim HK; Kang HC
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor-related thyroid dysfunction.
    Iwama S; Kobayashi T; Yasuda Y; Arima H
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
    Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
    Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
    Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
    Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
    Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
    [No Abstract]   [Full Text] [Related]  

  • 10. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
    Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
    Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
    Brancatella A; Lupi I; Montanelli L; Ricci D; Viola N; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Piaggi P; Molinaro E; Bianchi F; Aragona M; Antonuzzo A; Sbrana A; Lucchesi M; Chella A; Falcone A; Del Prato S; Elisei R; Marcocci C; Caturegli P; Santini F; Latrofa F
    J Endocr Soc; 2021 Sep; 5(9):bvab093. PubMed ID: 34337277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
    Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
    Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis.
    Ma Y; Ma X; Wang J; Wu S; Wang J; Cao B
    World J Surg Oncol; 2022 Jul; 20(1):242. PubMed ID: 35897018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
    Jaafar J; Fernandez E; Alwan H; Philippe J
    Endocr Connect; 2018 May; 7(5):R196-R211. PubMed ID: 29739808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models.
    Kim W; Cho YA; Kim DC; Jo AR; Min KH; Lee KE
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.